Abstract: This invention provides a therapeutic agent for inhibiting neovascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, and a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4. Based on the finding that vascularization is suppressed in CXCR4 knockout mice, it becomes possible to prepare a therapeutic agent for suppressing vascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, each of which comprises as the effective ingredient, a substance that inhibits the action of CXCR4, as well as to prepare a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4. Methods for treatment are made possible that use these therapeutic agents.

Abstract: The present invention discloses a screening method for a substance, which could be a therapeutic agent for diabetes with insulin resistance through regulating a function of a molecule involved in insulin signaling pathway. More specifically, the present invention discloses a screening method for a substance having hypoglycemic activity, which is characterized by contacting a sample to STAT-induced inhibitor of STAT function-1 in the presence of insulin, and by detecting inhibitory activity of STAT-induced inhibitor of STAT function-1 by a substance in the sample, as an index.

Abstract: This invention provides a growth inhibitor for leukemia cells comprising an antisense oligonucleotide derivative to Wilms' tumor gene (WT1).

Abstract: This invention provides a growth inhibitor for leukemia cells comprising an antisense oligonucleotide derivative to Wilms' tumor gene (WT1).

Abstract: Methods for inhibiting synovial cell growth and treating chronic rheumatoid arthritis are provided. The methods comprise administering a pharmaceutical composition comprising an interleukin-6 antagonist, such as an anti-IL-6 receptor antibody, and a physiologically acceptable carrier.

Abstract: Monoclonal antibodies recognizing gp130 protein and binding to the protein to inhibit IL-6 functions completely (that is to the same level as that is the absence of IL-6) when present in enough amount; a hybridoma producing the monoclonal antibody; a process for production of the monoclonal antibodies using the hybridoma; and an inhibitory agent for inhibition of physiological actions of IL-6 comprising the monoclonal antibodies.

Abstract: Mammal transcription factor APRF, process for the preparation of it, DNAs encoding the product, replication and expression vector comprising the DNA, host cells transformed or tranfected with the replication and expression vector, evaluating and screening method for searching an inhibitory agent on the function of APRF and an inhibitory agent against the function of the APRF. The peptide of the present invention (APRF) may be useful for complement or suppression of the function of APRF, screening an inhibitory agent against the function of APRF. Inhibiting agent containing the product as active ingredient of the present invention may be also useful for treatment of diseases related to cytokine such as IL-6, i.e. inflammatory diseases.

Abstract: Mammal transcription factor APRF, process for the preparation of it, DNAs encoding the product, replication and expression vector comprising the DNA, host cells transformed or tranfected with the replication and expression vector, evaluating and screening method for searching an inhibitory agent on the function of APRF and an inhibitory agent against the function of the APRF. The peptide of the present invention (APRF) may be useful for complement or suppression of the function of APRF, screening an inhibitory agent against the function of APRF. Inhibiting agent containing the product as active ingredient of the present invention may be also useful for treatment of diseases related to cytokine such as IL-6, i.e., inflammatory diseases.

Abstract: A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA, a process for producing and obtaining the BCDF, and compositions containing the BCDF are disclosed.

Abstract: A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA, a process for producing and obtaining the BCDF, compositions containing the BCDF and various therapeutic uses are disclosed.

Abstract: This invention relates to a gene which codes for the IL-6 gene expression inducing nuclear factor C/EBP2 capable of binding sequence-specifically to the palindrome structure SEQ ID NO:2 located in the transcriptional regulatory region of the IL-6 gene; an expression plasmid with the C/EBP2 gene incorporated therein; an transformant harboring the expression plasmid; a recombinant C/EBP2 obtained by expressing the C/EBP2 gene; and a method of producing the recombinant C/EBP2.

Abstract: Thrombocytopenia is treated by administering a subject suffering from thrombocytopenia a composition containing human B cell differentiation activity in combination with IL-3.

Abstract: This invention relates to a gene which codes for the IL-6 gene expression inducing nuclear factor C/EBP2 capable of binding sequence-specifically to the palindrome structure SEQ ID NO:2 located in the transcriptional regulatory region of the IL-6 gene; an expression plasmid with the C/EBP2 gene incorporated therein; an transformant harboring the expression plasmid; a recombinant C/EBP2 obtained by expressing the C/EBP2 gene; and a method of producing the recombinant C/EBP2.

Abstract: A composition and a method for supporting bone marrow transplantation are disclosed. The composition comprises a therapeutically acceptable amount of human B cell differentiation factor, or its biological equivalent, optionally in combination with an auxiliary agent selected from IL-1, IL-3, IL-4, IL-5, G-CSF, GM-CSF, and M-CSF. The composition also promotes the proliferation of hematopoietic cells in vitro.

Abstract: Thrombocytopenia is treated by administering to a subject a therapeutic amount of human B cell differentiation factor or its biological equivalent.